Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELQ-331
- Development stage
- Preclinical
- Lead developer
- Medicines for Malaria Venture
- Modality
- Small Molecules
- Administration
- Implant, Intramuscular, Oral
01
Overview
ELQ-331 (also known as MMV167) is a preclinical-stage, long-acting alkoxycarbonate ester prodrug of ELQ-300 (MMV055), a potent inhibitor of the parasite mitochondrial cytochrome bc1 complex (specifically targeting the Qi site). Developed to overcome the poor aqueous solubility and high crystallinity of ELQ-300, ELQ-331 is designed for long-acting injectable chemoprotection (LAI-C) against malaria. It undergoes rapid and complete conversion to the active antimalarial agent ELQ-300 in vivo, providing sustained protective blood concentrations. Research has demonstrated its potential to provide multi-month protection against *Plasmodium* infection and transmission with a single intramuscular injection or subdermal implant.
- Other names
- ELQ331ELQ-331ELQ 331
Beyond the preview
Go deeper on ELQ-331.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELQ-331.